camptothecin has been researched along with vasoactive intestinal peptide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikuno, N; Oka, M; Soda, H; Watanabe, M | 1 |
| Coy, DH; Fuselier, JA; Jensen, RT; Mantey, SA; Moody, TW | 1 |
| Koo, OM; Onyüksel, H; Rubinstein, I | 1 |
3 other study(ies) available for camptothecin and vasoactive intestinal peptide
| Article | Year |
|---|---|
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cecum; Cisplatin; Diarrhea; Enzyme Inhibitors; Hyperplasia; Ileum; Intestinal Mucosa; Irinotecan; Male; Mice; Mucins; Proliferating Cell Nuclear Antigen; Serotonin; Topoisomerase I Inhibitors; Vasoactive Intestinal Peptide | 1995 |
Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
Topics: 3T3 Cells; Animals; Breast Neoplasms; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Mice; Vasoactive Intestinal Peptide | 2007 |
Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Immunohistochemistry; Injections, Subcutaneous; Male; Mice; Mice, Inbred DBA; Micelles; Nanoparticles; Radiography; Topoisomerase I Inhibitors; Treatment Outcome; Vasoactive Intestinal Peptide | 2011 |